Get 50% OFF This Monsoon!
Kimia Biosciences
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Kimia Bio-sciences Limited (Formerly known Laurel Organics Limited) was incorporated in September, 1993 led by the Promoters, A K Bansal, K S Varma, Atul Sharma, A P Godiyal, D K Gupta and R K Bansal. The Company has own manufacturing of Bulk Drugs-APIs at its plant located at Gurgaon, Haryana. The Company is engaged into the business of Pharamaceutical products.
The company set up a bulk drug manufacturing unit at Gurgaon, Haryana, at a project cost of Rs 10.41 cr. It came out with a public issue in Feb.'95 to part-finance the project. Commercial production commenced in May '95.
During the 1998-99, the company has become a sick industrial units.
The Hon'ble BIFR vide order dated 27th December, 2005 had deregistered the Company as Sick Industrial Undertaking on the ground that 100% of the capacity was utilized for manufacture of the intermediate products for M/s Ranbaxy Laboratoty Limfted (RLL) and , thereby, turning-out to be an ancillary industrial Undertaking. .The Hon'ble AAIFR disposed the appeal of M/s Ranbaxy Lab. Ltd vide its Order dated 30.08.2006, directing them to file an application before the Ho'ble BIFR only to redress grievances. Therefore, M/s Ranbaxy Lab. Ltd had filed an application-dated 31.10.06 before the Hon'ble BIFR, requesting them to consider issuance of appropriate corrective orders. The Board has re-confirmed its earlier order. Therefore, despite negative net worth, the Company is out of BIFR purview.
During the year 2017-18, the Scheme of Arrangement for Amalgamation of the Company with M/s Kimia Biosciences Limited was made effective from September 17, 2018. Upon Scheme of Amalgamation becoming effective on 17.09.2018, M/s. Kimia Biosciences Limited Holding Company having 37,28,100 Equity Shares (50.48%) of Rs. 10/- each of the Company got merged under reverse merger with the Company.
Kimia Biosciences share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Kimia Biosciences indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Kimia Biosciences is valued compared to its competitors.
Kimia Biosciences PE ratio helps investors understand what is the market value of each stock compared to Kimia Biosciences 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Kimia Biosciences evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Kimia Biosciences generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Kimia Biosciences in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Kimia Biosciences shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Kimia Biosciences compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Kimia Biosciences over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Kimia Biosciences helps investors get an insight into when they can enter or exit the stock. Key components of Kimia Biosciences Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Kimia Biosciences shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Kimia Biosciences ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Kimia Biosciences provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Kimia Biosciences highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Kimia Biosciences .
The balance sheet presents a snapshot of Kimia Biosciences ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App